Patients from 22+ countriesPlan your visit →
lutetium-therapy
Blog

Latest from research and the clinic.

New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.

Medically reviewedUpdated 14 Nov 2024
Comparing Options26 Aug 2026

Can You Get Lu-177 PSMA Without Chemo First?

In March 2025, the FDA expanded its approval of lutetium Lu 177 vipivotide tetraxetan to cover mCRPC patients who have not yet had taxane chemotherapy. This article explains what changed, who now qualifies, and how sequencing decisions are shifting for men with PSMA-positive mCRPC.

9 min read
Access & Cost23 Aug 2026

Lutathera PRRT Cost in India for GEP-NET Patients

Lutathera (lutetium Lu-177 dotatate) is an approved targeted radiation therapy for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. This guide explains how it works, who qualifies, and what a full four-cycle PRRT course costs at Indian cancer centers compared to the United States.

8 min read
Patient Journey22 Aug 2026

Can You Still Work During Lu-177 PSMA Therapy?

Many men with mCRPC continue some form of work during Lu-177 PSMA therapy. This guide explains how treatment is scheduled, which side effects affect job performance, what radiation safety rules apply at home and in the workplace, and how to build a practical plan around each 6-week cycle.

9 min read
Considering Lu-177 Therapy21 Aug 2026

Does Lu-177 PSMA Therapy Cause Permanent Nerve Damage?

Nerve pain during Lu-177 PSMA therapy almost always traces to one of three identifiable causes - not to the therapy itself. Understanding which one applies to you changes how your care team can help.

8 min read
Second Opinions21 Aug 2026

GEP-NET Second-Line Therapy When PRRT Is Not an Option

Not all GEP-NET patients meet the criteria for PRRT with lutetium Lu-177 dotatate - but being told it is not suitable does not mean treatment options are exhausted. This article covers the evidence-based second-line paths available, from targeted oral therapy to liver-directed treatment, and explains when a second opinion on eligibility is worth pursuing.

7 min read
Patient Journey20 Aug 2026

Maintaining Muscle Mass During Lu-177 PSMA Therapy

Men with mCRPC on Lu-177 PSMA therapy face muscle loss from three directions at once - the cancer itself, testosterone suppression from ADT, and reduced activity between cycles. Here is what nutrition and exercise evidence says you can do about it.

8 min read
Considering Lu-177 Therapy20 Aug 2026

What Your PSMA-PET Results Mean for Lu-177 Eligibility

Your PSMA-PET scan report holds the key to Lu-177 eligibility - but terms like SUV max, PSMA-avid, and heterogeneous uptake are rarely explained in plain language. This guide decodes what each finding means for your treatment options in metastatic prostate cancer.

9 min read
Access & Cost19 Aug 2026

Lu-177 PSMA Therapy Cost in India for International Patients

A full course of Lu-177 PSMA therapy in India typically costs USD 20,000 to USD 48,000, compared with USD 170,000 or more in the United States. This guide breaks down every cost - drug, hospital, scans, and accommodation - so international patients can plan a realistic budget.

8 min read
Considering Lu-177 Therapy17 Aug 2026

Lu-177 PSMA Now Available Earlier for mCRPC Patients

The rules about when you can access Lu-177 PSMA therapy for metastatic castration-resistant prostate cancer have changed. A 2025 FDA expansion now allows some men to receive this targeted radiation treatment before taxane-based chemotherapy.

8 min read
Considering Lu-177 Therapy17 Aug 2026

Lu-177 PSMA Therapy Timing and Fertility in Men Under 60

If you are under 60 with metastatic castration-resistant prostate cancer, Lu-177 PSMA therapy may fit your case - but younger patients face unique questions about treatment timing, genetic testing, and fertility preservation that rarely come up in older men.

8 min read
Patient Journey17 Aug 2026

Lu-177 DOTATATE Retreatment After GEP-NET Progression

If your GEP-NET has progressed after an initial course of Lu-177 DOTATATE, a second round of PRRT may be possible. This article explains who qualifies, what the evidence shows, and how to pursue a retreatment eligibility review.

9 min read
Patient Journey14 Aug 2026

Lu-177 DOTATATE Diarrhea in NET Patients

Diarrhea and bowel changes during Lu-177 DOTATATE PRRT can come from two very different sources - the tumor itself, or the treatment process. This guide explains both and shows NET patients how to manage bowel side effects across each cycle.

8 min read

How we choose what to write about

We focus on three kinds of content:

  1. Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
  2. Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
  3. India updates - new centers, new approvals, new policies that affect Indian and India-bound patients

Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Blog - Page 3 - Lutetium Therapy Research, News, and Patient FAQs | lutetium-therapy